{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:55:48Z","timestamp":1790913348950,"version":"4.1.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.bcp.2009.05.003","type":"journal-article","created":{"date-parts":[[2009,5,10]],"date-time":"2009-05-10T08:16:30Z","timestamp":1241943390000},"page":"677-685","source":"Crossref","is-referenced-by-count":110,"title":["Multiple roles for nicotine in Parkinson's disease"],"prefix":"10.1016","volume":"78","author":[{"given":"Maryka","family":"Quik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luping Z.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraja","family":"Parameswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanuja","family":"Bordia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiomara A.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2009.05.003_bib1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.pneurobio.2008.05.003","article-title":"Progress in Parkinson's disease-where do we stand?","volume":"85","author":"Toulouse","year":"2008","journal-title":"Prog Neurobiol"},{"issue":"Suppl. 2","key":"10.1016\/j.bcp.2009.05.003_bib2","first-page":"S30","article-title":"The basal ganglia in Parkinson's disease: current concepts and unexplained observations","volume":"64","author":"Obeso","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bcp.2009.05.003_bib3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/bmb\/ldn013","article-title":"A review of Parkinson's disease","volume":"86","author":"Davie","year":"2008","journal-title":"Br Med Bull"},{"key":"10.1016\/j.bcp.2009.05.003_bib4","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00702-004-0251-7","article-title":"Levodopa-induced dyskinesia in Parkinson's disease","volume":"112","author":"Brotchie","year":"2005","journal-title":"J Neural Transm"},{"key":"10.1016\/j.bcp.2009.05.003_bib5","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1471-4159.2006.04124.x","article-title":"Post-versus presynaptic plasticity in l-DOPA-induced dyskinesia","volume":"99","author":"Cenci","year":"2006","journal-title":"J Neurochem"},{"key":"10.1016\/j.bcp.2009.05.003_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/0471142301.ns0925s41","article-title":"Ratings of l-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice","author":"Cenci","year":"2007","journal-title":"Curr Protoc Neurosci"},{"key":"10.1016\/j.bcp.2009.05.003_bib7","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/mds.20936","article-title":"Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure","volume":"21","author":"Fox","year":"2006","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2009.05.003_bib8","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.parkreldis.2004.11.005","article-title":"Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors","volume":"11","author":"Guigoni","year":"2005","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.bcp.2009.05.003_bib9","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1523\/JNEUROSCI.5059-04.2005","article-title":"Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia","volume":"25","author":"Guigoni","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.bcp.2009.05.003_bib10","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.tips.2005.06.007","article-title":"New ideas on the origin of l-dopa-induced dyskinesias: age, genes and neural plasticity","volume":"26","author":"Linazasoro","year":"2005","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bcp.2009.05.003_bib11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.tips.2005.05.002","article-title":"The \u2018magic\u2019 of l-dopa: why is it the gold standard Parkinson's disease therapy?","volume":"26","author":"Mercuri","year":"2005","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bcp.2009.05.003_bib12","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S1474-4422(06)70521-X","article-title":"Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications","volume":"5","author":"Olanow","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bcp.2009.05.003_bib13","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.tips.2006.08.002","article-title":"Opioids and motor complications in Parkinson's disease","volume":"27","author":"Samadi","year":"2006","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bcp.2009.05.003_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/mds.21475","article-title":"Levodopa-induced dyskinesias","author":"Fabbrini","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.bcp.2009.05.003_bib15","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/mds.21900","article-title":"Nicotine and Parkinson's disease: implications for therapy","volume":"23","author":"Quik","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.bcp.2009.05.003_bib16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00702-007-0852-z","article-title":"Pharmacological treatment of Parkinson's disease: life beyond dopamine D2\/D3 receptors?","volume":"115","author":"Linazasoro","year":"2008","journal-title":"J Neural Transm"},{"key":"10.1016\/j.bcp.2009.05.003_bib17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0079-6123(08)00922-9","article-title":"Serotonin-dopamine interaction in the induction and maintenance of l-DOPA-induced dyskinesias","volume":"172","author":"Carta","year":"2008","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.bcp.2009.05.003_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awn235","article-title":"Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of l-DOPA-induced dyskinesia","author":"Munoz","year":"2008","journal-title":"Brain"},{"issue":"Suppl. 1","key":"10.1016\/j.bcp.2009.05.003_bib19","doi-asserted-by":"crossref","first-page":"S283","DOI":"10.1038\/sj.bjp.0707510","article-title":"Presynaptic nicotinic receptors: a dynamic and diverse cholinergic filter of striatal dopamine neurotransmission","volume":"153","author":"Exley","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2009.05.003_bib20","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.bcp.2007.07.032","article-title":"The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum","volume":"74","author":"Grady","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2009.05.003_bib21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.coph.2004.12.002","article-title":"Nicotine: from molecular mechanisms to behaviour","volume":"5","author":"Wonnacott","year":"2005","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.bcp.2009.05.003_bib22","doi-asserted-by":"crossref","DOI":"10.1111\/j.1471-4159.2008.05307.x","article-title":"Release-enhancing pre-synaptic muscarinic and nicotinic receptors co-exist and interact on dopaminergic nerve endings of rat nucleus accumbens","author":"Grilli","year":"2008","journal-title":"J Neurochem"},{"key":"10.1016\/j.bcp.2009.05.003_bib23","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.neuroscience.2005.08.035","article-title":"Midbrain muscarinic receptors modulate morphine-induced accumbal and striatal dopamine efflux in the rat","volume":"136","author":"Miller","year":"2005","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2009.05.003_bib24","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/j.1460-9568.2005.04017.x","article-title":"Midbrain muscarinic receptor mechanisms underlying regulation of mesoaccumbens and nigrostriatal dopaminergic transmission in the rat","volume":"21","author":"Miller","year":"2005","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.bcp.2009.05.003_bib25","doi-asserted-by":"crossref","first-page":"492","DOI":"10.2741\/2695","article-title":"Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease","volume":"13","author":"Picciotto","year":"2008","journal-title":"Front Biosci"},{"key":"10.1016\/j.bcp.2009.05.003_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.tips.2007.03.001","article-title":"Nicotine neuroprotection against nigrostriatal damage: importance of the animal model","author":"Quik","year":"2007","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bcp.2009.05.003_bib27","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2174\/1568007023339166","article-title":"The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration","volume":"1","author":"O\u2019Neill","year":"2002","journal-title":"Curr Drug Target CNS Neurol Disord"},{"key":"10.1016\/j.bcp.2009.05.003_bib28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1124\/jpet.108.140897","article-title":"Continuous and intermittent nicotine treatment reduces l-DOPA-induced dyskinesias in a rat model of Parkinson's disease","volume":"327","author":"Bordia","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2009.05.003_bib29","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ana.21203","article-title":"Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys","volume":"62","author":"Quik","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bcp.2009.05.003_bib30","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1212\/01.wnl.0000256374.50227.4b","article-title":"Temporal relationship between cigarette smoking and risk of Parkinson disease","volume":"68","author":"Thacker","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2009.05.003_bib31","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/archneur.64.7.990","article-title":"Pooled analysis of tobacco use and risk of Parkinson disease","volume":"64","author":"Ritz","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1016\/j.bcp.2009.05.003_bib32","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/mds.20587","article-title":"Smokeless tobacco use and the risk of Parkinson's disease mortality","volume":"20","author":"O\u2019Reilly","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.bcp.2009.05.003_bib33","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/mds.20029","article-title":"Smoking and Parkinson's disease: systematic review of prospective studies","volume":"19","author":"Allam","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.bcp.2009.05.003_bib34","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1212\/WNL.58.4.581","article-title":"Smoking and Parkinson's disease in twins","volume":"58","author":"Tanner","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2009.05.003_bib35","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2165\/00002512-200118110-00001","article-title":"Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease","volume":"18","author":"Ross","year":"2001","journal-title":"Drugs Aging"},{"key":"10.1016\/j.bcp.2009.05.003_bib36","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.10028","article-title":"Cigarette smoking and the incidence of Parkinson's disease in two prospective studies","volume":"50","author":"Hernan","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bcp.2009.05.003_bib37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1212\/WNL.52.1.115","article-title":"Smoking and Parkinson's disease: a dose-response relationship","volume":"52","author":"Gorell","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2009.05.003_bib38","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/oxfordjournals.bmb.a011533","article-title":"Beneficial effects of nicotine and cigarette smoking: the real, the possible and the spurious","volume":"52","author":"Baron","year":"1996","journal-title":"Br Med Bull"},{"key":"10.1016\/j.bcp.2009.05.003_bib39","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1212\/WNL.45.6.1041","article-title":"Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue?","volume":"45","author":"Morens","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2009.05.003_bib40","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-3-211-45295-0_28","article-title":"Nicotine induces brain CYP enzymes: relevance to Parkinson's disease","author":"Miksys","year":"2006","journal-title":"J Neural Transm Suppl"},{"key":"10.1016\/j.bcp.2009.05.003_bib41","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1471-4159.2009.06011.x","article-title":"Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys","volume":"109","author":"Huang","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bcp.2009.05.003_bib42","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1111\/j.1471-4159.2006.04078.x","article-title":"Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates","volume":"98","author":"Quik","year":"2006","journal-title":"J Neurochem"},{"key":"10.1016\/j.bcp.2009.05.003_bib43","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF02245195","article-title":"The short-term effect of nicotine chewing gum in patients with Parkinson's disease","volume":"117","author":"Clemens","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bcp.2009.05.003_bib44","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/1531-8257(199911)14:6<1011::AID-MDS1016>3.0.CO;2-F","article-title":"Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration","volume":"14","author":"Ebersbach","year":"1999","journal-title":"Mov Disord"},{"key":"10.1016\/j.bcp.2009.05.003_bib45","first-page":"33","article-title":"Effects of nicotine chewing gum on UPDRS score and P300 in early-onset parkinsonism","volume":"51","author":"Mitsuoka","year":"2002","journal-title":"Hiroshima J Med Sci"},{"key":"10.1016\/j.bcp.2009.05.003_bib46","first-page":"274","article-title":"The effects of nicotine on Parkinson's disease","volume":"43","author":"Kelton","year":"2000","journal-title":"Brain Cogn"},{"key":"10.1016\/j.bcp.2009.05.003_bib47","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1212\/WNL.57.6.1032","article-title":"Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study","volume":"57","author":"Vieregge","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2009.05.003_bib48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0278-5846(03)00172-6","article-title":"Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease","volume":"28","author":"Lemay","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.bcp.2009.05.003_bib49","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/0022-510X(93)90150-W","article-title":"Effects of smoking in patients with early-onset Parkinson's disease","volume":"117","author":"Ishikawa","year":"1993","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.bcp.2009.05.003_bib50","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF02244882","article-title":"Nicotine may relieve symptoms of Parkinson's disease","volume":"116","author":"Fagerstrom","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bcp.2009.05.003_bib51","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/mds.21177","article-title":"Smoking-responsive juvenile-onset Parkinsonism","volume":"22","author":"Hanagasi","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.bcp.2009.05.003_bib52","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1468-1331.2007.01949.x","article-title":"Chronic high dose transdermal nicotine in Parkinson's disease: an open trial","volume":"14","author":"Villafane","year":"2007","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.bcp.2009.05.003_bib53","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/mds.21010","article-title":"Behavioral models of Parkinson's disease in rodents: a new look at an old problem","volume":"21","author":"Meredith","year":"2006","journal-title":"Mov Disord"},{"issue":"Suppl 3","key":"10.1016\/j.bcp.2009.05.003_bib54","doi-asserted-by":"crossref","first-page":"S570","DOI":"10.1002\/mds.22019","article-title":"Molecular mechanisms underlying levodopa-induced dyskinesia","volume":"23","author":"Calabresi","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.bcp.2009.05.003_bib55","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1002\/ana.21453","article-title":"How do you treat motor complications in Parkinson's disease: medicine, surgery, or both?","volume":"64","author":"Fahn","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bcp.2009.05.003_bib56","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0079-6123(08)00923-0","article-title":"Parkinson's disease\u2014opportunities for novel therapeutics to reduce the problems of levodopa therapy","volume":"172","author":"Fox","year":"2008","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.bcp.2009.05.003_bib57","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrn2471","article-title":"Molecular mechanisms of l-DOPA-induced dyskinesia","volume":"9","author":"Jenner","year":"2008","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.bcp.2009.05.003_bib58","article-title":"Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?","author":"Nadjar","year":"2008","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.bcp.2009.05.003_bib59","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.bcp.2007.05.023","article-title":"Heterogeneity and complexity of native brain nicotinic receptors","volume":"74","author":"Gotti","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2009.05.003_bib60","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.bcp.2007.06.015","article-title":"Nicotinic receptors as CNS targets for Parkinson's disease","volume":"74","author":"Quik","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2009.05.003_bib61","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1146\/annurev.pharmtox.47.120505.105214","article-title":"Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system","volume":"47","author":"Dani","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.bcp.2009.05.003_bib62","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1152\/physrev.00015.2008","article-title":"Mammalian nicotinic acetylcholine receptors: from structure to function","volume":"89","author":"Albuquerque","year":"2009","journal-title":"Physiol Rev"},{"key":"10.1016\/j.bcp.2009.05.003_bib63","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.neuropharm.2008.07.041","article-title":"Diversity of vertebrate nicotinic acetylcholine receptors","volume":"56","author":"Millar","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2009.05.003_bib64","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1124\/jpet.105.094375","article-title":"Striatal alpha6* nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapy","volume":"316","author":"Quik","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2009.05.003_bib65","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/neu.10150","article-title":"Cholinergic interneuron characteristics and nicotinic properties in the striatum","volume":"53","author":"Zhou","year":"2002","journal-title":"J Neurobiol"},{"key":"10.1016\/j.bcp.2009.05.003_bib66","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1038\/sj.npp.1301617","article-title":"alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens","volume":"33","author":"Exley","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2009.05.003_bib67","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1111\/j.1471-4159.2008.05266.x","article-title":"The neuronal nicotinic acetylcholine receptors alpha 4* and alpha 6* differentially modulate dopamine release in mouse striatal slices","volume":"105","author":"Meyer","year":"2008","journal-title":"J Neurochem"},{"key":"10.1016\/j.bcp.2009.05.003_bib68","doi-asserted-by":"crossref","DOI":"10.1124\/mol.108.053801","article-title":"Prominent role of {alpha}3\/{alpha}6{beta}2* nAChRs in regulating evoked dopamine release in primate putamen; effect of long-term nicotine treatment","author":"Perez","year":"2009","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bcp.2009.05.003_bib69","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1124\/mol.108.048843","article-title":"Long-term nicotine treatment differentially regulates striatal alpha6alpha4beta2* and alpha6(nonalpha4)beta2* nAChR expression and function","volume":"74","author":"Perez","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bcp.2009.05.003_bib70","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1124\/mol.65.6.1526","article-title":"Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice","volume":"65","author":"Salminen","year":"2004","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bcp.2009.05.003_bib71","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.107.121228","article-title":"Chronic nicotine differentially regulates {alpha}6- and {beta}3-containing Nicotinic Cholinergic Receptors in Rat Brain","author":"Perry","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2009.05.003_bib72","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1124\/mol.107.035998","article-title":"Nigrostriatal damage preferentially decreases a subpopulation of {alpha}6{beta}2* nAChRs in mouse, monkey and Parkinson's disease striatum","volume":"72","author":"Bordia","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bcp.2009.05.003_bib73","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0006-8993(00)03087-0","article-title":"Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra","volume":"888","author":"Costa","year":"2001","journal-title":"Brain Res"},{"key":"10.1016\/j.bcp.2009.05.003_bib74","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/sj.bjp.0703989","article-title":"Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice","volume":"132","author":"Ryan","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2009.05.003_bib75","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.tips.2004.04.006","article-title":"Nicotinic acetylcholine receptors and the regulation of neuronal signalling","volume":"25","author":"Dajas-Bailador","year":"2004","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bcp.2009.05.003_bib76","doi-asserted-by":"crossref","first-page":"E885","DOI":"10.1208\/aapsj070486","article-title":"Neuronal nicotinic acetylcholine receptor expression and function on nonneuronal cells","volume":"7","author":"Gahring","year":"2005","journal-title":"Aaps J"},{"key":"10.1016\/j.bcp.2009.05.003_bib77","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1172\/JCI30555","article-title":"Physiology and immunology of the cholinergic antiinflammatory pathway","volume":"117","author":"Tracey","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2009.05.003_bib78","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0306-4522(97)00323-0","article-title":"Acute intermittent nicotine treatment produces regional increases of basic fibroblast growth factor messenger RNA and protein in the tel- and diencephalon of the rat","volume":"83","author":"Belluardo","year":"1998","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2009.05.003_bib79","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0169-328X(99)00266-1","article-title":"The nicotinic acetylcholine receptor agonist (+\/\u2212)-epibatidine increases FGF-2 mRNA and protein levels in the rat brain","volume":"74","author":"Belluardo","year":"1999","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.bcp.2009.05.003_bib80","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.mcn.2006.08.011","article-title":"BDNF up-regulates alpha7 nicotinic acetylcholine receptor levels on subpopulations of hippocampal interneurons","volume":"33","author":"Massey","year":"2006","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.bcp.2009.05.003_bib81","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1523\/JNEUROSCI.0055-04.2004","article-title":"Brain-derived neurotrophic factor and trkB signaling in parasympathetic neurons: relevance to regulating alpha7-containing nicotinic receptors and synaptic function","volume":"24","author":"Zhou","year":"2004","journal-title":"J Neurosci"},{"key":"10.1016\/j.bcp.2009.05.003_bib82","article-title":"Chronic but not acute nAChR stimulation reduces l-dopa-induced dyskinesias in parkinsonian rats","author":"Bordia","year":"2009","journal-title":"Society for Neuroscience Abstracts"},{"key":"10.1016\/j.bcp.2009.05.003_bib83","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/0006-8993(88)90092-3","article-title":"Chronic nicotine treatment counteracts the disappearance of tyrosine-hydroxylase-immunoreactive nerve cell bodies, dendrites and terminals in the mesostriatal dopamine system of the male rat after partial hemitransection","volume":"455","author":"Janson","year":"1988","journal-title":"Brain Res"},{"key":"10.1016\/j.bcp.2009.05.003_bib84","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0006-2952(02)01070-5","article-title":"Effects of (\u2212)-nicotine and (\u2212)-cotinine on 6-hydroxydopamine-induced oxidative stress and neurotoxicity: relevance for Parkinson's disease","volume":"64","author":"Soto-Otero","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2009.05.003_bib85","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/10298420290015863","article-title":"Presynaptic involvement in the nicotine prevention of the dopamine loss provoked by 6-OHDA administration in the substantia nigra","volume":"4","author":"Abin-Carriquiry","year":"2002","journal-title":"Neurotox Res"},{"key":"10.1016\/j.bcp.2009.05.003_bib86","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.neuropharm.2006.04.015","article-title":"Nicotine, but neither the alpha4beta2 ligand RJR2403 nor an alpha7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle","volume":"51","author":"Visanji","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2009.05.003_bib87","first-page":"232","article-title":"Differential effects of acute and chronic nicotine treatment on MPTP-(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced degeneration of nigrostriatal dopamine neurons in the black mouse","volume":"70","author":"Janson","year":"1992","journal-title":"Clin Investig"},{"key":"10.1016\/j.bcp.2009.05.003_bib88","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0166-4328(00)00197-2","article-title":"Central nicotinic receptors, neurotrophic factors and neuroprotection","volume":"113","author":"Belluardo","year":"2000","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bcp.2009.05.003_bib89","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/BF01273324","article-title":"Striatal increase of neurotrophic factors as a mechanism of nicotine protection in experimental parkinsonism","volume":"104","author":"Maggio","year":"1997","journal-title":"J Neural Transm"},{"key":"10.1016\/j.bcp.2009.05.003_bib90","first-page":"113","article-title":"Involvement of nicotinic acetylcholine receptors in the protection of dopamine terminals in experimental parkinsonism","volume":"16","author":"Dajas","year":"2001","journal-title":"Funct Neurol"},{"key":"10.1016\/j.bcp.2009.05.003_bib91","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0006-8993(00)03198-X","article-title":"Nicotine, but not cotinine, partially protects dopaminergic neurons against MPTP-induced degeneration in mice","volume":"890","author":"Parain","year":"2001","journal-title":"Brain Res"},{"key":"10.1016\/j.bcp.2009.05.003_bib92","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1523\/JNEUROSCI.0215-06.2006","article-title":"Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates","volume":"26","author":"Quik","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.bcp.2009.05.003_bib93","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1124\/jpet.106.106997","article-title":"Partial recovery of striatal nicotinic receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys with chronic oral nicotine","volume":"319","author":"Bordia","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2009.05.003_bib94","first-page":"323","article-title":"The effect of chronic nicotine treatment on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degneration of nigrostriatal dopamine neurons in the black mouse","volume":"1","author":"Janson","year":"1991","journal-title":"Adv Pharmacol Sci"},{"key":"10.1016\/j.bcp.2009.05.003_bib95","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0028-3908(90)90019-N","article-title":"Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity by tobacco smoke","volume":"29","author":"Carr","year":"1990","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2009.05.003_bib96","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0304-3940(91)90804-3","article-title":"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: partial protection against striato-nigral dopamine depletion in C57BL\/6J mice by cigarette smoke exposure and by beta-naphthoflavone-pretreatment","volume":"127","author":"Shahi","year":"1991","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bcp.2009.05.003_bib97","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1006\/phrs.1998.0337","article-title":"Effects of nicotine on 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced depression of striatal dopamine content and spontaneous locomotor activity in C57 black mice","volume":"38","author":"Gao","year":"1998","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bcp.2009.05.003_bib98","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0006-8993(03)03195-0","article-title":"Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin","volume":"984","author":"Parain","year":"2003","journal-title":"Brain Res"},{"key":"10.1016\/j.bcp.2009.05.003_bib99","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0304-3940(87)90152-2","article-title":"Exposure to cigarette smoke does not decrease the neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice","volume":"74","author":"Perry","year":"1987","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bcp.2009.05.003_bib100","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/0304-3940(88)90094-8","article-title":"Effect of chronic oral nicotine on dopaminergic function in the MPTP-treated mouse","volume":"93","author":"Sershen","year":"1988","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bcp.2009.05.003_bib101","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1471-4159.1992.tb09786.x","article-title":"Nicotine enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity","volume":"58","author":"Behmand","year":"1992","journal-title":"J Neurochem"},{"key":"10.1016\/j.bcp.2009.05.003_bib102","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0022-3565(25)22396-5","article-title":"Enhanced MPTP neurotoxicity after treatment with isoflurophate or cholinergic agonists","volume":"270","author":"Hadjiconstantinou","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2009.05.003_bib103","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/PL00005264","article-title":"Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo","volume":"358","author":"Ferger","year":"1998","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.bcp.2009.05.003_bib104","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1471-4159.2006.04177.x","article-title":"Nicotine partially protects against paraquat-induced nigrostriatal damage in mice; link to alpha6beta2* nAChRs","volume":"100","author":"Khwaja","year":"2007","journal-title":"J Neurochem"},{"key":"10.1016\/j.bcp.2009.05.003_bib105","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1471-4159.2004.02177.x","article-title":"Loss of alpha-conotoxinMII- and A85380-sensitive nicotinic receptors in Parkinson's disease striatum","volume":"88","author":"Quik","year":"2004","journal-title":"J Neurochem"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295209003736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295209003736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T10:02:04Z","timestamp":1739095324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295209003736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":105,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0006295209003736"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2009.05.003","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}